{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:10:18Z","timestamp":1776280218452,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alcohol septal ablation (ASA) is recommended for moderate to severe symptomatic patients with hypertrophic obstructive cardiomyopathy. The current guidelines don not recommend particular alcohol doses and the amount of alcohol injected into the septal artery is based more on the interventionalist\u2019s decision rather than on systematic evidence. Our objective is to execute a comprehensive assessment of the efficacy and safety of low alcohol doses (1\u20132\u00a0ml)) in comparison to large ones (2\u20134\u00a0ml).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Multiple databases, encompassing PubMed, WOS, Scopus, Embase, and Cochrane library were systemically assessed from inception to October 2023. Randomized controlled trials (RCTs) and observational studies comparing low-alcohol and high-alcohol dose in patients with HOCM was included. The main outcome was creatine kinase-MB (CK-MB). The secondary ones are septal thickness, left ventricular outflow pressure gradient, and atrioventricular (AV) block.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eight studies, with a total of 1446 individuals, were finally involved in our investigation. low alcohol doses showed lower CK-MB levels relative to high ones (MD=-0.93, 95% CI [-1.15 to -0.72], <jats:italic>P<\/jats:italic>\u2009=\u20090.00001). Furthermore, in terms of septal thickness, left ventricular outflow pressure gradient, and AV block, neither of the two doses was preferred.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We propose that the low alcohol dose is equally effective as the high dose. moreover, the low alcohol dose was associated with a lower CK-MB levels in comparison to the high one.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>PROSPERO registration<\/jats:title>\n                <jats:p>CRD42024511537<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-024-04194-2","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T09:07:55Z","timestamp":1730970475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy and safety of alcohol septal ablation stratified by alcohol dosage for patients with hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Ahmed","family":"Elshahat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Ellabban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mostafa","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Diaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Bakr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fayed","family":"Rzk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Bedak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Eid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Elaraby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Hamouda","family":"Elkasaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1257-3450","authenticated-orcid":false,"given":"Ahmed","family":"Abdelaziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"4194_CR1","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1161\/01.CIR.0000066323.15244.54","volume":"107","author":"P Richard","year":"2003","unstructured":"Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107:2227\u201332. https:\/\/doi.org\/10.1161\/01.CIR.0000066323.15244.54.","journal-title":"Circulation"},{"key":"4194_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.cir.92.4.785","volume":"92","author":"BJ Maron","year":"1995","unstructured":"Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary artery Risk Development in (Young). Adults Circulation. 1995;92:785\u20139. https:\/\/doi.org\/10.1161\/01.cir.92.4.785.","journal-title":"Adults Circulation"},{"key":"4194_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.amjmed.2003.05.009","volume":"116","author":"Y Zou","year":"2004","unstructured":"Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004;116:14\u20138. https:\/\/doi.org\/10.1016\/j.amjmed.2003.05.009.","journal-title":"Am J Med"},{"key":"4194_CR4","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/s0735-1097(99)00039-x","volume":"33","author":"BJ Maron","year":"1999","unstructured":"Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol. 1999;33:1590\u20135. https:\/\/doi.org\/10.1016\/s0735-1097(99)00039-x.","journal-title":"J Am Coll Cardiol"},{"key":"4194_CR5","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249\u201354. https:\/\/doi.org\/10.1016\/j.jacc.2015.01.019.","journal-title":"J Am Coll Cardiol"},{"key":"4194_CR6","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733\u201379. https:\/\/doi.org\/10.1093\/eurheartj\/ehu284.","journal-title":"Eur Heart J"},{"key":"4194_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ejmg.2010.07.007","volume":"53","author":"G Millat","year":"2010","unstructured":"Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, Da Costa A, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet. 2010;53:261\u20137. https:\/\/doi.org\/10.1016\/j.ejmg.2010.07.007.","journal-title":"Eur J Med Genet"},{"key":"4194_CR8","volume-title":"Hypertrophic obstructive cardiomyopathy","author":"MA Raj","year":"2024","unstructured":"Raj MA, Ranka S, Goyal A. Hypertrophic obstructive cardiomyopathy. Treasure Island (FL): StatPearls Publishing;: StatPearls; 2024."},{"key":"4194_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3238\/arztebl.2011.0209","volume":"108","author":"C Prinz","year":"2011","unstructured":"Prinz C, Farr M, Hering D, Horstkotte D, Faber L. The diagnosis and treatment of hypertrophic cardiomyopathy. Dtsch Arztebl Int. 2011;108:209\u201315. https:\/\/doi.org\/10.3238\/arztebl.2011.0209.","journal-title":"Dtsch Arztebl Int"},{"key":"4194_CR10","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1016\/j.jacc.2020.08.044","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. J Am Coll Cardiol. 2020;76:3022\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.044.","journal-title":"J Am Coll Cardiol"},{"key":"4194_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0140-6736(95)91267-3","volume":"346","author":"U Sigwart","year":"1995","unstructured":"Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(95)91267-3.","journal-title":"Lancet"},{"key":"4194_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1161\/CIRCRESAHA.116.309348","volume":"121","author":"RA Nishimura","year":"2017","unstructured":"Nishimura RA, Seggewiss H, Schaff HV. Hypertrophic obstructive cardiomyopathy: Surgical Myectomy and septal ablation. Circ Res. 2017;121:771\u201383. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.309348.","journal-title":"Circ Res"},{"key":"4194_CR13","doi-asserted-by":"publisher","first-page":"318","DOI":"10.21037\/acs.2017.04.03","volume":"6","author":"D Hang","year":"2017","unstructured":"Hang D, Nguyen A, Schaff HV. Surgical treatment for hypertrophic cardiomyopathy: a historical perspective. Ann Cardiothorac Surg. 2017;6:318\u201328. https:\/\/doi.org\/10.21037\/acs.2017.04.03.","journal-title":"Ann Cardiothorac Surg"},{"key":"4194_CR14","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. n.d. https:\/\/training.cochrane.org\/handbook (accessed February 29, 2024)."},{"key":"4194_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4194_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Reviews. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Reviews"},{"key":"4194_CR17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"4194_CR18","unstructured":"The Newcastle-Ottawa. Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses \u2013 ScienceOpen n.d. https:\/\/www.scienceopen.com\/document?vid=54b48470-4655-4081-b5d4-e8ebe8d1792e (accessed February 29, 2024)."},{"key":"4194_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. JBI Evid Implement. 2018;16:195. https:\/\/doi.org\/10.1097\/XEB.0000000000000141.","journal-title":"JBI Evid Implement"},{"key":"4194_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/ccd.20176","volume":"63","author":"J Veselka","year":"2004","unstructured":"Veselka J, Proch\u00e1zkov\u00e1 S, Duchonov\u00e1 R, Bolomov\u00e1-Homolov\u00e1 I, P\u00e1len\u00edckov\u00e1 J, Tesar D, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv. 2004;63:231\u20135. https:\/\/doi.org\/10.1002\/ccd.20176.","journal-title":"Catheter Cardiovasc Interv"},{"key":"4194_CR21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.amjcard.2004.10.050","volume":"95","author":"J Veselka","year":"2005","unstructured":"Veselka J, Duchonov\u00e1 R, Proch\u00e1zkov\u00e1 S, P\u00e1len\u00edckov\u00e1 J, Sorajja P, Tesar D. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol. 2005;95:675\u20138. https:\/\/doi.org\/10.1016\/j.amjcard.2004.10.050.","journal-title":"Am J Cardiol"},{"key":"4194_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00380-008-1083-4","volume":"24","author":"J Veselka","year":"2009","unstructured":"Veselka J, Zem\u00e1nek D, Tomasov P, Duchonov\u00e1 R, Linhartov\u00e1 K. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1\u00a0ml) is still effective. Heart Vessels. 2009;24:27\u201331. https:\/\/doi.org\/10.1007\/s00380-008-1083-4.","journal-title":"Heart Vessels"},{"key":"4194_CR23","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1253\/circj.70.1550","volume":"70","author":"J Veselka","year":"2006","unstructured":"Veselka J, Duchonov\u00e1 R, P\u00e1len\u00edckova J, Zem\u00e1nek D, Tiserov\u00e1 M, Linhartov\u00e1 K, et al. Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a single-center prospective, and randomized study. Circ J. 2006;70:1550\u20132. https:\/\/doi.org\/10.1253\/circj.70.1550.","journal-title":"Circ J"},{"key":"4194_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ijcard.2021.02.056","volume":"333","author":"J Veselka","year":"2021","unstructured":"Veselka J, Faber L, Liebregts M, Cooper R, Januska J, Kashtanov M, et al. Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2021;333:127\u201332. https:\/\/doi.org\/10.1016\/j.ijcard.2021.02.056.","journal-title":"Int J Cardiol"},{"key":"4194_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.cjca.2011.09.001","volume":"27","author":"J Veselka","year":"2011","unstructured":"Veselka J, Toma\u0161ov P, Zem\u00e1nek D. Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years. Can J Cardiol. 2011;27:763\u20137. https:\/\/doi.org\/10.1016\/j.cjca.2011.09.001.","journal-title":"Can J Cardiol"},{"key":"4194_CR26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/ccd.26448","volume":"88","author":"M Liebregts","year":"2016","unstructured":"Liebregts M, Vriesendorp PA, Steggerda RC, Schinkel AFL, Balt JC, Ten Cate FJ, et al. Effect of alcohol dosage on long-term outcomes after alcohol septal ablation in patients with hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2016;88:945\u201352. https:\/\/doi.org\/10.1002\/ccd.26448.","journal-title":"Catheter Cardiovasc Interv"},{"key":"4194_CR27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.amjcard.2008.01.003","volume":"101","author":"C van der Lee","year":"2008","unstructured":"van der Lee C, Scholzel B, ten Berg JM, Geleijnse ML, Idzerda HH, van Domburg RT, et al. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. Am J Cardiol. 2008;101:1315\u201320. https:\/\/doi.org\/10.1016\/j.amjcard.2008.01.003.","journal-title":"Am J Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04194-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04194-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04194-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T09:08:59Z","timestamp":1730970539000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04194-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4194"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04194-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"24 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"624"}}